ENA0000GenomicsNINDShttps://www.ebi.ac.uk/ena/browser/view/PRJNA310289Homo sapiensThis is a multi-center, randomized, double-blind, placebo-controlled trial of CoQ involving 609 ambulatory subjects with HD who are not requiring skilled care or institutionalization. Eligible subjects were randomized to receive either CoQ 2400 mg/day or matching placebo. Subjects were followed prospectively and systematically for 60 months of double-blind observation. The primary outcome variable is a combination of time to death (for subjects who die) and the change from baseline to Month 60 in Total Functional Capacity (TFC) score (for subjects who survive). The primary hypothesis of the study is that chronic treatment of early-stage HD subjects with high-dosage CoQ will slow the progressive functional decline of HD.ENAcoenzyme Q10, other disease, E, human disease, ion (1-), CoQ10, ubisemiquinone, ubiquinone 50, CoQ 10, ubiquinone 10, disorders, co-enzyme Q10, (all-E)-isomer, Z, non-neoplastic, disease, diseases, Q-ter, E)-isomer, 3-dimethoxy-5-methyl-6-decaprenylbenzoquinone, Diseases, ubiquinone Q10, disease or disorder, Bio-Quinone Q10, (Z, 2, condition, disorder, Homo sapiens disease, diseases and disorders, medical condition., ubidecarenone, ubisemiquinone radicalhuman being, human., man0.00.00.00.00.00falseHomo sapiensCoenzyme Q10 in Huntington’s Disease (2CARE)2022-05-122016-02-02PRJNA3102899606